| Tami Jollie-trottier, Phd, Pllc | |
|
202 Joyful Circle Belcourt ND 58316-5831 | |
| (701) 550-5120 | |
| Not Available |
| Full Name | Tami Jollie-trottier, Phd, Pllc |
|---|---|
| Speciality | Psychologist - Psychoanalysis |
| Location | 202 Joyful Circle, Belcourt, North Dakota |
| Authorized Official Name and Position | Tami S Jollie--trottier (OWNER CLINICAL PSYCHOLOGIST) |
| Authorized Official Contact | 7015505120 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Tami Jollie-trottier, Phd, Pllc Po Box 810 Belcourt ND 58316-0810 Ph: (701) 550-5120 | Tami Jollie-trottier, Phd, Pllc 202 Joyful Circle Belcourt ND 58316-5831 Ph: (701) 550-5120 |
| NPI Number | 1255921276 |
|---|---|
| Provider Enumeration Date | 01/23/2021 |
| Last Update Date | 08/11/2021 |
| Certification Date | 08/11/2021 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255921276 | NPI | - | NPPES |
| 14827 | Medicaid | ND | |
| 1460514 | Medicaid | ND |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103TP0814X | Psychologist - Psychoanalysis | (* (Not Available)) | Primary |
News Archive
Moderate to severe chronic obstructive pulmonary disease (COPD) may be an auto-immunity problem, according to researchers in Spain, who studied the presence of auto-antibodies in patients with COPD and compared them to levels of control subjects. They found that a significant number of patients with COPD had significant levels of auto-antibodies circulating in their blood, about 5 to 10 times the level in controls.
Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).
Universal Detection Technology, a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, reported today test results for its passive zone security sensor, developed through its partnership with Precision Sensors Instrumentation (PSI), a leading developer of security sensors.
Optivia Biotechnology Inc., a leading provider of in vitro transporter assay services, today announced the launch of the OptiDDITM Suite, a novel assay panel that assesses the most clinically significant transporter-related drug-drug interactions (DDIs), as identified by the International Transporter Consortium (ITC) in its report "Membrane Transporters in Drug Development" (Nature Reviews-Drug Discovery, March 2010).
The stem cell transplant regimen that was commonly used in the United States to treat advanced neuroblastoma in children appears to be more toxic than the equally effective regimen employed in Europe and Egypt, according to a new study to be presented at the 26th annual meeting of the American Society of Pediatric Hematology Oncology in Miami April 24-27.
› Verified 4 days ago